AbbVie Inc. $ABBV Shares Purchased by Tsfg LLC

Tsfg LLC increased its stake in shares of AbbVie Inc. (NYSE:ABBV) by 5.3% during the second quarter, HoldingsChannel.com reports. The institutional investor owned 134,486 shares of the company’s stock after acquiring an additional 6,734 shares during the quarter. AbbVie makes up about 4.3% of Tsfg LLC’s investment portfolio, making the stock its 4th largest position. Tsfg LLC’s holdings in AbbVie were worth $33,842,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in ABBV. Ranch Capital Advisors Inc. raised its position in shares of AbbVie by 37.0% during the 1st quarter. Ranch Capital Advisors Inc. now owns 14,888 shares of the company’s stock valued at $3,238,000 after buying an additional 4,017 shares during the period. Capital Advisors Inc. OK grew its position in AbbVie by 11.2% in the second quarter. Capital Advisors Inc. OK now owns 447,129 shares of the company’s stock worth $112,516,000 after acquiring an additional 45,132 shares during the period. Danica Pension Livsforsikringsaktieselskab acquired a new stake in AbbVie during the second quarter worth $23,557,000. Wedge Capital Management L L P NC increased its stake in AbbVie by 7.5% during the second quarter. Wedge Capital Management L L P NC now owns 134,579 shares of the company’s stock worth $33,865,000 after acquiring an additional 9,380 shares during the last quarter. Finally, Mission Wealth Management LP raised its position in AbbVie by 119.1% in the second quarter. Mission Wealth Management LP now owns 69,052 shares of the company’s stock valued at $17,376,000 after purchasing an additional 37,531 shares during the period. Institutional investors and hedge funds own 70.23% of the company’s stock.

AbbVie Stock Up 0.9%

AbbVie stock opened at $251.04 on Thursday. The firm has a market cap of $443.53 billion, a PE ratio of 70.92, a price-to-earnings-growth ratio of 1.13 and a beta of 0.29. AbbVie Inc. has a 52-week low of $190.75 and a 52-week high of $267.47. The company’s 50 day moving average is $254.66 and its two-hundred day moving average is $230.55.

AbbVie (NYSE:ABBV) last posted its quarterly earnings results on Friday, July 31st. The company reported $3.65 EPS for the quarter, topping the consensus estimate of $3.61 by $0.04. AbbVie had a net margin of 9.80% and a negative return on equity of 422.07%. The business had revenue of $16.99 billion during the quarter, compared to the consensus estimate of $16.80 billion. During the same quarter in the previous year, the firm posted $2.97 earnings per share. The company’s quarterly revenue was up 10.2% compared to the same quarter last year. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. On average, equities research analysts anticipate that AbbVie Inc. will post 14.05 earnings per share for the current fiscal year.

AbbVie Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Friday, August 14th. Shareholders of record on Wednesday, July 15th were issued a dividend of $1.73 per share. The ex-dividend date was Wednesday, July 15th. This represents a $6.92 annualized dividend and a yield of 2.8%. AbbVie’s dividend payout ratio is 195.48%.

Insiders Place Their Bets

In other AbbVie news, EVP Nicholas Donoghoe sold 32,710 shares of the stock in a transaction dated Friday, August 14th. The stock was sold at an average price of $250.00, for a total value of $8,177,500.00. Following the sale, the executive vice president owned 74,430 shares of the company’s stock, valued at $18,607,500. This trade represents a 30.53% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 0.06% of the stock is currently owned by company insiders.

Analyst Ratings Changes

Several brokerages have recently commented on ABBV. BNP Paribas Exane upped their price target on AbbVie from $218.00 to $247.00 and gave the company a “neutral” rating in a research note on Tuesday, August 11th. Cantor Fitzgerald boosted their price objective on shares of AbbVie from $265.00 to $285.00 and gave the company an “overweight” rating in a report on Monday, August 3rd. Canaccord Genuity Group increased their target price on shares of AbbVie from $282.00 to $290.00 and gave the stock a “buy” rating in a research note on Monday, August 3rd. Morgan Stanley reiterated an “overweight” rating and set a $296.00 price target on shares of AbbVie in a research report on Monday, August 3rd. Finally, Royal Bank Of Canada boosted their price target on shares of AbbVie from $260.00 to $280.00 and gave the company an “outperform” rating in a research note on Friday, July 10th. Two research analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and five have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $275.95.

About AbbVie

AbbVie Inc (NYSE: ABBV) is a global biopharmaceutical company that discovers, develops and commercializes medicines across immunology, oncology, neuroscience, eye care, aesthetics and other specialty areas. The company was established in 2013 after separating from Abbott Laboratories, which retained Abbott’s diversified medical products and diagnostics businesses while AbbVie focused on research-based pharmaceuticals.

AbbVie’s immunology portfolio includes Skyrizi (risankizumab) and Rinvoq (upadacitinib), which are used to treat several inflammatory conditions.